Emil N. Nachman

I'll research this attorney before drafting.

Emil N. Nachman — patent litigation summary

Focus areas. Nachman's tracked patent docket is concentrated in pharmaceutical/Hatch-Waxman litigation on behalf of a brand manufacturer: all three tracked matters are Novartis plaintiff-side ANDA suits over the fingolimod (Gilenya) dosing-regimen patent family, tried and briefed in the District of Delaware. His firm bio lists him in Gibson Dunn's Intellectual Property, Life Sciences, Appellate and Constitutional Law, and General Commercial Litigation groups, and his scientific training (M.Sc. in Molecular Genetics, B.Sc. in Molecular and Cell Biology, University of Toronto) is consistent with a life-sciences/chemistry-biology patent practice. There is no evidence in the tracked set or in searchable coverage of a Wi-Fi/standards, software, or mechanical practice.

Side preference. Every tracked appearance is plaintiff-side — he has acted for the patent owner/NDA holder asserting infringement against generic filers (3 plaintiff, 0 defendant). That said, a Delaware docket entry in Alnylam Pharmaceuticals, Inc. v. Moderna, Inc. (D. Del. 1:22-cv-00335) records a pro hac vice appearance for the Moderna defendants by an "Emil N. Nachman" of Gibson Dunn, which would be a defense-side biotech representation outside the tracked set; I could not independently confirm identity or scope beyond the docket entry, so treat it as an unverified addition. Overall characterization: patent-owner-side pharma litigator with some defense-side biotech exposure.

Firm context. Gibson, Dunn & Crutcher, New York office, where he is identified on the firm's website as a litigation associate. All three tracked matters list Gibson Dunn as firm of record. No prior firm history surfaced in searchable sources; I could not verify any earlier employer.

Notable matters and outcomes. The most prominent tracked case is Novartis Pharmaceuticals Corp. v. HEC Pharm Co., Ltd. (D. Del.; Fed. Cir. No. 2021-1070), in which the district court in August 2020 upheld the validity of U.S. Patent No. 9,187,405 and entered a permanent injunction running to the patent's December 2027 expiry. A Federal Circuit panel affirmed in January 2022, then granted rehearing and reversed in June 2022 on written-description grounds (negative claim limitation / no-loading-dose limitation), with Chief Justice Roberts staying the mandate in September 2022 on Novartis's emergency application. Nachman appears on the Federal Circuit filings in that appeal. Novartis v. Accord Healthcare (D. Del. 1:18-cv-01043) was the related multi-defendant Gilenya action, where the docket reflects extensive Daubert and expert-discovery motion practice and where his tracked role is trial counsel. I did not verify a final disposition for the Accord or Handa matters (Novartis has publicly reported settlements with several ANDA filers), so any settlement terms should be confirmed against the dockets.

PTAB / IPR. No IPR, PGR, or other PTAB appearances by this attorney were found in the searches conducted. His verified experience is district court and Federal Circuit appellate work. Flag this as an absence of evidence rather than a confirmed absence — a full PTAB docket check was not performed.

Bar and education. Admitted in New York; J.D., Harvard Law School (2018); M.Sc. (2015) and B.Sc. (2012), University of Toronto. Sources: Gibson Dunn attorney profile (gibsondunn.com/lawyer/nachman-emil/), CourtListener and Justia docket entries for the Delaware actions, Federal Circuit filings in No. 2021-1070, and Novartis press releases/media coverage of the Gilenya decisions (Law360/National Law Review summaries of the Supreme Court stay).